Abstract 135P
Background
Two classical models have been proposed for the development of colorectal cancer (CRC) from colon epithelial cells, transformation of adenoma and serrated polyps to cancer. However, clinical data showed that there is still a certain amount of CRC is not derived from the above two pathways, forming the theoretical island of CRC pathogenesis. Laterally spreading tumor (LST) is an important precancerous lesion of CRC, while the molecular mechanism of it's carcinogenesis remained unclear.
Methods
We proposed a two-stage cascade mutation hypothesis for LST cancerization. Based on the mRNA data of 25711 samples from 980 healthy donors in the genotype-tissue expression, pan-cancer mRNA-sequencing and survival data.We performed a differential expression and survival analysis of ATM, ANO5, APC, and TP53 in pan-cancer and adjacent normal samples. Furthermore, we validated the noneffective role of PIK3CA signaling pathway in two cell lines, LS174T and SW1116 by constructing three SiRNA (PIK3CA-SiRNA-1, PIK3CA-SiRNA-2, PIK3CA-SiRNA-3), to confirm the vital role of TGFβ and p53 signaling pathway involving in LST cancerization.
Results
The expression profiles of ATM, ANO5, APC and TP53 in normal and pan-cancer samples were significantly downregulated in rectal adenocarcinoma, colon adenocarcinoma, and their joint samples. In contrast, TP53 showed an obviously higher level in all of above samples. ATM, ANO5, APC, and TP53 expression were correlated with the overall survival of colorectal cancer patients. ATM and ANO5, which closely related to the Golgi apparatus fragmentation in LST samples presented a significant changes. The SiRNA interference test showed that the expression level of PIK3CA was not significantly different from the control group.
Conclusions
These findings suggested that early APC mutations induced a Golgi fragmentation event, weakened the expression of wild-type TP53 transcription factor MDM2 and TP73, modulated the stability of mutant TP53, ultimately promoted the carcinogenesis process of the LST. The PI3K signaling pathway is not closely associated with LST carcinogenesis. These observations suggest the existence of a unique and novel pathway for the development of CRC from LST.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China; Gansu Medical College.
Disclosure
The authors have declared no conflicts of interest.
Resources from the same session
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract